EUVIMEDEUVIMED entdecken
Open Access

Kang Ru Plus reverses osimertinib resistance in lung adenocarcinoma via suppression of EGFR/PI3K/AKT signaling

Thomas G Mhone, Wei-Wen Kuo, Chih-Ying Chi, Chia-Hua Kuo, Tsung-Jung Ho, Yu-Ling Wu, Yueh-Min Lin, Ming-Cheng Chen, Chih-Yang Huang, Shinn-Zong Lin

American Journal of Cancer Research · 2026 · 16 (6) · 2389-2406

DOI: 10.62347/curf9339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Thomas G Mhone und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien, Taiwan. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

EGFR signalingKang Ru Plusapoptosislung adenocarcinomanetwork pharmacologyosimertinib resistancephytochemical profiling

Autor:innen und Institutionen

  • Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien, Taiwan.
  • Center for Molecular Medicine in Traditional Chinese Medicine, E-Da Hospital, E-Da Healthcare Group Kaohsiung, Taiwan.
  • Department of Biological Science and Technology, College of Life Sciences, China Medical University Taichung, Taiwan.
  • School of Pharmacy, China Medical University Taichung, Taiwan.
  • Laboratory of Exercise Biochemistry, The Education University of Hong Kong New Territories, Hong Kong.
  • Soochow University, School of Physical Education and Sports Science Suzhou, Jiangsu, China.

Zitieren

APA

Mhone, T. G., Kuo, W. W., Chi, C. Y., Kuo, C. H., Ho, T. J., Wu, Y. L., Lin, Y. M., Chen, M. C., Huang, C. Y., & Lin, S. Z. (2026). Kang Ru Plus reverses osimertinib resistance in lung adenocarcinoma via suppression of EGFR/PI3K/AKT signaling. American Journal of Cancer Research, 16(6), 2389-2406. https://doi.org/10.62347/curf9339

Vancouver

Mhone TG, Kuo WW, Chi CY, Kuo CH, Ho TJ, Wu YL, et al. Kang Ru Plus reverses osimertinib resistance in lung adenocarcinoma via suppression of EGFR/PI3K/AKT signaling. American Journal of Cancer Research. 2026;16(6):2389-2406. doi:10.62347/curf9339

BibTeX
@article{Mhone2026,
  author = {Mhone, Thomas G and Kuo, Wei-Wen and Chi, Chih-Ying and Kuo, Chia-Hua and Ho, Tsung-Jung and Wu, Yu-Ling and Lin, Yueh-Min and Chen, Ming-Cheng and Huang, Chih-Yang and Lin, Shinn-Zong},
  title = {Kang Ru Plus reverses osimertinib resistance in lung adenocarcinoma via suppression of EGFR/PI3K/AKT signaling},
  journal = {American Journal of Cancer Research},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {2389--2406},
  doi = {10.62347/curf9339}
}
Kostenlos starten →